Previous 10 | Next 10 |
2023-03-22 19:05:07 ET Predictive Oncology, Inc. (POAI) Q4 2022 Earnings Conference Call March 22, 2023 12:00 PM ET Company Participants Theresa Ferguson - Senior Director of Marketing Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers ...
Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, ...
2023-03-21 17:26:45 ET Predictive Oncology press release ( NASDAQ: POAI ): FY GAAP EPS of -$0.35. Revenue of $1.51M (+6.3% Y/Y). For further details see: Predictive Oncology GAAP EPS of -$0.35, revenue of $1.51M
EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (...
--News Direct-- Predictive Oncology chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, join Proactive's Natalie Stoberman to discuss their new partnership for new cancer drug development. The collaboration will utilize Predictive ...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, i...
2023-03-17 07:29:21 ET Predictive Oncology ( NASDAQ: POAI ) is collaborating with Cancer Research Horizons (CRH) to develop cancer drugs. CRH is the innovation arm of Cancer Research UK – one of the world's largest charitable funders of cancer research,...
EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partner...
2023-03-17 06:58:02 ET Predictive Oncology's ( NASDAQ: POAI ) declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock for each outstanding common share held of record, as of March 27. The company said the outstanding shares of ...
EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate on...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...